ΔNp63α and MicroRNA: Leveraging the Epithelial-Mesenchymal Transition

Andrew J. Stacy

Michael P. Craig  
*Wright State University - Main Campus*, michael.p.craig@wright.edu

Suraj Sakaram

Madhavi Kadakia  
*Wright State University - Main Campus*, madhavi.kadakia@wright.edu

Follow this and additional works at: https://corescholar.libraries.wright.edu/bmb

Part of the Molecular Biology Commons

Repository Citation
https://corescholar.libraries.wright.edu/bmb/28

This Article is brought to you for free and open access by the Biochemistry and Molecular Biology at CORE Scholar. It has been accepted for inclusion in Biochemistry and Molecular Biology Faculty Publications by an authorized administrator of CORE Scholar. For more information, please contact library-corescholar@wright.edu.
ΔNp63α and microRNAs: leveraging the epithelial-mesenchymal transition

Andrew J. Stacy1, Michael P. Craig1, Suraj Sakaram1 and Madhavi Kadakia1

1 Department of Biochemistry and Molecular Biology, Wright State University, Dayton, OH, USA

Correspondence to: Madhavi Kadakia, email: Madhavi.Kadakia@Wright.edu

Keywords: EMT, p63, miRNA, signaling, biomarker

Received: September 07, 2016    Accepted: November 22, 2016    Published: December 04, 2016

ABSTRACT

The epithelial-mesenchymal transition (EMT) is a cellular reprogramming mechanism that is an underlying cause of cancer metastasis. Recent investigations have uncovered an intricate network of regulation involving the TGFβ, Wnt, and Notch signaling pathways and small regulatory RNA species called microRNAs (miRNAs). The activity of a transcription factor vital to the maintenance of epithelial stemness, ΔNp63α, has been shown to modulate the activity of these EMT pathways to either repress or promote EMT. Furthermore, ΔNp63α is a known regulator of miRNA, including those directly involved in EMT. This review discusses the evidence of ΔNp63α as a master regulator of EMT components and miRNA, highlighting the need for a deeper understanding of its role in EMT. This expanded knowledge may provide a basis for new developments in the diagnosis and treatment of metastatic cancer.

INTRODUCTION

Cancer cell metastasis is the leading cause of death from cancer, however, the cellular mechanisms of metastasis remain incompletely characterized [1]. The process by which carcinoma cells can become migratory and invasive is proposed to occur via EMT, a cellular reprogramming mechanism by which epithelial cells acquire a motile mesenchymal phenotype, leading to the migration of cells to nonadjacent target sites [2, 3]. Once at these target sites these cells will regain an epithelial phenotype via a process called the Mesenchymal-Epithelial transition (MET) [4]. Epithelial cells are characterized by cell-cell adhesion, non-motility as a result of extracellular matrix anchorage, and an apical-basal polarity [2]. Mesenchymal cells typically lack cell-cell adhesion, degrade the extracellular matrix to become motile and invasive, display apoptotic resistance, and exhibit a lack of polarity [5]. EMT is essential for developmental processes such as gastrulation, neural crest formation, and wound healing; however, EMT can also lead to pathological states, such as organ fibrosis and tumor cell metastasis [6].

Many epithelial markers, including tight junction proteins such as zona occludens-1 (ZO-1), occludins, and the claudins, as well as the adherens junction protein epithelial cadherin (E-cadherin), are repressed during EMT [7]. The most frequently observed predictive harbinger of EMT progression is the downregulation of E-cadherin [8]. Mesenchymal cells instead express neural cadherin (N-cadherin), vimentin, an intermediate filament protein that is vital to mesenchymal organelle cytoskeletal arrangement, and fibronectin, a glycoprotein that functions in migration [9]. Promotion of EMT is accomplished primarily by the transcription factors TWIST, SNAIL, SLUG, and ZEB [8]. SNAIL1 and SLUG (also known as SNAIL2) bind to and repress the E-cadherin promoter CDH1 and trigger the switch to N-cadherin [10, 11]. TWIST is known to result in downregulation of E-cadherin and promote EMT through upregulation of SLUG [12]. ZEB1 and ZEB2 (ZEB1/2) also repress E-cadherin and upregulate matrix metalloproteinases (MMPs) to degrade the extracellular matrix, which allows for increased cellular mobility [13, 14].

An additional transcription factor recently shown to inhibit EMT is p63, a member of the p53 family. The p63 gene encodes six primary isoforms through differential promoter usage and C-terminal splicing [15]. The alternative promoters result in two classes of p63 constituting either a full-length transactivation domain at the N-terminus, designated TAp63, or a truncated N-terminus lacking the transactivation domain, designated ΔNp63 [16]. Alternative splicing of TAp63 and ΔNp63 create distinct C-termini, designated α, β, and γ. All of these isoforms contain a DNA binding domain and an oligomerization domain; however, the α isoforms also
contain a sterile alpha motif (SAM) protein-protein binding domain and a trans-inhibitory domain [17]. This review primarily focuses on the most physiologically relevant isoform, ΔNp63α, unless otherwise noted. ΔNp63α is highly expressed in the basal layer of epithelia where it plays a role in cellular proliferation and is downregulated in suprabasal keratinocytes [16]. p63 is vital to epithelial morphogenesis, as p63 null mice are born lacking limbs or stratified epithelium resulting in their death shortly following birth due to dehydration [18]. Additionally, p63 knockout mice have no hair or teeth, and exhibit defects in mammary gland development [19].

ΔNp63α has a vital role in the inhibition of EMT and promotion of the epithelial phenotype. ΔNp63α downregulates mesenchymal genes and simultaneously upregulates epithelial genes, particularly those involved in cell adhesion, such as Claudin1, and integrins involved with cellular adhesion to the extracellular matrix [20-22]. ΔNp63α also induces the expression of the transcription factor inhibitor of differentiation-3 (ID3), which inhibits the expression of both an E-cadherin transcriptional repressor, E2A, and an extracellular matrix degradation enzyme, MMP2 [23]. Inhibiting ΔNp63α upregulates genes that promote mesenchymal morphology and motility, such as N-cadherin, leading to increased cell invasion and metastatic potential [24]. ΔNp63α is transcriptionally repressed by SnaI1, thus suggesting that p63 is also downstream of known EMT-related transcription factors [25]. Loss of ΔNp63α can also lead to a reduction in MET [26].

**ΔNp63α INVOLVEMENT WITH EMT SIGNALING PATHWAYS**

Multiple signaling pathways, including Transforming Growth Factor β (TGFβ), Wnt, and Notch, are involved in the cellular regulation of TWIST, SNAIL, SLUG, and ZEB. The representative signaling cascades are shown in Figure 1 [8]. Inhibition of these pathways, their components, or their target genes can repress EMT [27-30]. The interplay between these pathways and ΔNp63α is dynamic. The evidence presented here indicates that several pathways modulate ΔNp63α expression and activity to induce rather than inhibit EMT. The involvement of ΔNp63α in these pathways is summarized in Figure 2.

**TRANSFORMING GROWTH FACTOR β SIGNALING**

The TGFβ pathway regulates multiple cellular processes, such as proliferation, differentiation, cytoskeletal rearrangements, metastasis, and apoptosis [31]. Signaling is activated by the TGFβ ligand cytokine superfamily (TGFβ1/2/3) and Bone Morphogenic Protein 2 (BMP2)-BMP7, with TGFβ1 being the principal driver of EMT [31]. Binding of a TGFβ ligand to its receptor induces SMAD2/3 phosphorylation, resulting in a complex with SMAD4 and translocation to the nucleus to target genes for transcription [32]. SMAD signaling leads to the upregulation of SNAIL1, ZEB1/2, and the non-histone chromatin binding protein high mobility group A2 (HMG2A) [33]. HMG2A forms a complex with SMAD3-SMAD4 to enhance SNAIL1, SLUG, and TWIST transcription to promote EMT [34].

SMAD proteins alone bind DNA weakly and, as a functional necessity, associate with other transcriptional factors to increase their binding affinity, including ΔNp63α (Figure 2A). Signaling induced by TGFβ1 drives formation of a complex consisting of ΔNp63α, mutant p53, and SMAD2, which results in the repression of ΔNp63α transcriptional activity while promoting SMAD2 activity, resulting in increased invasiveness and metastasis [35]. ΔNp63α also transcriptionally induces BMP7 in breast tumors [36]. SMAD1/5/8, activated by BMP7, have been shown to interact with ΔNp63α to regulate BMP transcriptional targets, including SNAIL [37]. Other reports further support ΔNp63α as a SMAD co-factor, because ΔNp63α in the presence of TGFβ signaling silences E-cadherin while increasing fibronectin expression [38]. It can therefore be concluded that SMAD proteins interact with and alter the activity of ΔNp63α, resulting in promotion rather than inhibition of EMT. Supporting this conclusion is the observation that re-expressing ΔNp63α in mesenchyme-like cells does not completely restore the epithelial phenotype [21]. This evidence suggests that the SMAD-ΔNp63α complex competes with free ΔNp63α for access to response elements and explains why reintroduction of ΔNp63α in the presence of TGFβ signaling does not fully induce an epithelial phenotype. This raises the hypothesis that EMT signaling pathways can modulate ΔNp63α activity to promote EMT, as ΔNp63α has also been observed to promote EMT in mammary and other tissues [39, 40].

**WNT SIGNALING**

Extracellular matrix-associated Wnt ligands bind to Frizzled and low-density lipoprotein receptor-related protein (LRP) receptors to initiate Wnt signaling. In the absence of Wnt ligand activation, β-catenin is phosphorylated by glycogen synthase kinase-3β (GSK3β), which is in complex with AXIN and adenomatosis polyposis coli (APC). This phosphorylation ultimately targets β-catenin for proteasomal degradation. Induction of Wnt signaling results in activation of Dishevelled (DVL), which recruits GSK3β and Axin to the plasma membrane and preventing GSK3β from phosphorylating β-catenin [41]. This leads to the accumulation of β-catenin and its translocation to the nucleus, where it complexes with the T cell factor (TCF)/Lymphocyte enhancer enhancer factor
(LEF) transcription factors to induce the transcription of EMT components such as vimentin, SNAIL1, and SLUG [41]. Wnt signaling can participate in crosstalk with TGFβ signaling since β-catenin, as well as SMAD2/3 in complex with SMAD4, can activate TCF/LEF [9]. Intriguingly, most colorectal tumors exhibit an increase in intracellular β-catenin yet do not display mesenchymal features [5]. This indicates that β-catenin acts as a co-activator for the expression of EMT transcription factors but cannot induce them alone. Thus, β-catenin is a molecular node providing crosstalk between Wnt and other EMT signaling pathways, including the TGFβ and Notch pathways.

There are contradictory observations regarding the role of ΔNp63α within the Wnt pathway (Figure 2B). It has been observed that ΔNp63α decreases β-catenin phosphorylation to allow for β-catenin nuclear accumulation in Saos-2 osteosarcoma cells, where ΔNp63α/β-catenin can then associate to promote TCF/LEF to induce upregulation of mesenchymal biomarkers vimentin and Snail [42]. A second study using non-small cell lung carcinoma cells (H1299) and human embryonic kidney cells (HeK293) cells found that ΔNp63α opposes Wnt signaling and inhibits Wnt downstream targets, thus suggesting the observed contradictions of ΔNp63α-modulation of Wnt signaling may be due to differing experimental conditions [43]. Endogenous ΔNp63α was found to induce vimentin, SNAIL, and TWIST in esophageal squamous carcinoma cell lines to promote migration/invasion in a β-catenin-dependent manner, while showing little to no effect on EMT biomarkers in esophageal adenocarcinoma cell lines [44]. Supporting this observation, ΔNp63α was found to activate Wnt target genes in a squamous cell carcinoma cell line (FaDu), while repressing Wnt response elements in HEK293 cells [45]. A potential explanation for the positive regulation of β-catenin by ΔNp63α could depend on the status of AKT activation. ΔNp63α is a negative transcriptional regulator of PTEN, promoting AKT phosphorylation and activity [46]. AKT subsequently phosphorylates GSK3β, leading to its inactivation and allowing for β-catenin nuclear accumulation [47]. However, it appears that ΔNp63α can also compete with β-catenin for binding to Wnt response elements to inhibit Wnt signaling [45]. This contradiction highlights the need for further investigation. Together these results suggest that invasive carcinomas can influence the activity of ΔNp63α to promote a mesenchymal phenotype, either by Akt signaling or potentially even through a tertiary co-factor such as a SMAD or mutant p53, which could associate with ΔNp63α/β-Catenin.

**NOTCH SIGNALING**

The Notch pathway is involved in cellular proliferation, differentiation, apoptosis, and survival [48]. Notch signaling is initiated when a cell expressing a Notch transmembrane receptor (NOTCH1-4), consisting of an extracellular and intracellular (NICD) domain, comes into contact with another cell expressing one of the transmembrane Notch ligands, including Delta-like ligand 1/3/4 (DLL1/3/4) and Jagged1/2 [49]. This interaction induces the proteolytic cleavage of NOTCH...
to form the NICD. Once cleaved, the NICD translocates to the nucleus where it interacts with the DNA-bound transcriptional repressor CBF-1-Suppressor of Hairless/Lag1 (CSL) [49]. This complex displaces corepressors and recruits the co-activating Mastermind-like protein (MAML) to form the Notch-CSL-MAML complex [50]. The NOTCH-CSL-MAML complex subsequently recruits members of the Notch transcriptional complex to activate gene expression [51]. For example, Notch signaling upregulates Nuclear Factor-κB (NF-κB) [5, 8]. NF-κB can induce EMT by upregulating Snail1, Slug, and Lef-1, as well as by stabilizing β-catenin and modulating TGFβ signaling activity [5, 8].

Cells expressing ΔNp63α can induce Notch signaling on adjacent cells while simultaneously repressing this pathway within themselves. This is due in part to crosstalk between NOTCH and the PI3K-AKT pathway (Figure 2C). As mentioned in the previous section, ΔNp63α can promote AKT phosphorylation by inhibiting PTEN expression [46]. AKT leads to the activation of mTORC1, which phosphorylates STAT3 to induce its translocation to the nucleus. STAT3 then upregulates ΔNp63α, which influences Notch signaling by inducing the expression of the Notch ligand Jagged1. Jagged1 then induces Notch signaling in adjacent cells. Additionally, there is negative feedback between ΔNp63α and Notch pathway components. DLL1 and Jagged1 ligands signal through the NOTCH1 receptor, inducing NF-κB, which then inhibits the activity and promotes the proteasomal degradation of ΔNp63α by a poorly understood mechanism in squamous cell carcinoma and non-small cell lung cancer [52]. Conversely, ΔNp63α inhibits Notch-dependent transcription and represses NOTCH1 receptor expression, indirectly inhibiting the activity of NF-κB [53]. The relationship between Notch signaling and ΔNp63α is important to the establishment of the ectoderm, as ΔNp63α expression is lost through the suprabasal layers with increased Notch activity [54]. However, the Notch-ΔNp63α relationship has potential implications in a tumor microenvironment. Cells overexpressing ΔNp63α can express Jagged1 and stimulate NF-κB through NOTCH1 in adjacent cells expressing little to no ΔNp63α to potentially promote EMT [55]. This could also help explain contradictory reports with regard to EMT correlated with ΔNp63α.

In conclusion, ΔNp63α is involved with components of signaling pathways found to induce EMT. Therefore, there is a clear connection established between ΔNp63α and the cellular regulation of EMT.

**MICRORNA**s THAT INHIBIT EMT

miRNAs are small non-coding RNAs shown to target EMT transcription factors, as shown in Table 1 [56]. miRNA are approximately 17-23 nucleotides in length and inhibit gene expression by preventing translation of target mRNA. miRNA are transcribed from the genome and processed by the RNase III endonuclease DROSHA [57]. Alternatively, miRNA known as Mirtrons are transcribed from the introns of genes and do not require processing by DROSHA [58]. Both the intrinsic canonical and intronic pre-miRNA are then transported to the cytoplasm to be processed by the RNase III enzyme DICER [57]. The miRNA are then loaded into a multi-protein complex, the RNA Induced Silencing Complex (RISC). miRNAs contain a 2-8 nucleotide seed sequence, called the guide strand, which recognizes a complementary sequence in the 3'-UTR region of target mRNA, resulting in the degradation or translational repression of the target transcript [57]. Multiple miRNAs may be targeted by a single miRNA. This includes EMT transcription factors, invasion and migratory proteins, regulators of miRNA biosynthesis such as DROSHA and DICER, and the primary focus of this review, ΔNp63α.

ΔNp63α has been implicated in the direct transcriptional control of miRNA responsible for regulating many cellular processes, including EMT (Tables 2 and 3) [59]. For example, ΔNp63α promotes the expression of miR-205 by binding directly to its promoter and recruiting RNA polymerase II [60]. This identifies ΔNp63α as a negative regulator of EMT, as miR-205 in turn targets ZEB1/2 [60, 61]. Loss of ΔNp63α and miR-205 have also been correlated to poor clinical outcomes

**Table 1: miRNAs shown to inhibit or promote EMT**

<table>
<thead>
<tr>
<th>miRNAs</th>
<th>Target(s)</th>
<th>Reference</th>
</tr>
</thead>
<tbody>
<tr>
<td>Let-7</td>
<td>HMGA2</td>
<td>[65]</td>
</tr>
<tr>
<td>1</td>
<td>SLUG</td>
<td>[68]</td>
</tr>
<tr>
<td>9</td>
<td>NF-κB, E-cadherin</td>
<td>[90, 91]</td>
</tr>
<tr>
<td>10b</td>
<td>HOXD10</td>
<td>[92, 93]</td>
</tr>
<tr>
<td>29b</td>
<td>SNAIL1</td>
<td>[79]</td>
</tr>
<tr>
<td>30</td>
<td>SNAIL1</td>
<td>[80]</td>
</tr>
<tr>
<td>34a, 34b, 34c</td>
<td>ZEB1, SNAIL1, SLUG</td>
<td>[78]</td>
</tr>
<tr>
<td>130b</td>
<td>ZEB1</td>
<td>[74]</td>
</tr>
<tr>
<td>138</td>
<td>ZEB2</td>
<td>[76]</td>
</tr>
<tr>
<td>192</td>
<td>ZEB2</td>
<td>[125]</td>
</tr>
<tr>
<td>141, 200a, 200b, 429</td>
<td>ZEB1/2, β-catenin</td>
<td>[71, 72]</td>
</tr>
<tr>
<td>203</td>
<td>SNAIL1, SLUG</td>
<td>[69, 81]</td>
</tr>
<tr>
<td>204</td>
<td>TGFBRII</td>
<td>[67]</td>
</tr>
<tr>
<td>205</td>
<td>ZEB1/2</td>
<td>[61]</td>
</tr>
<tr>
<td>221, 222</td>
<td>TRPS1</td>
<td>[89]</td>
</tr>
<tr>
<td>365</td>
<td>HMGA2</td>
<td>[64]</td>
</tr>
<tr>
<td>455-3p</td>
<td>RUNX2</td>
<td>[87]</td>
</tr>
</tbody>
</table>

www.impactjournals.com/oncotarget
In patients [59]. In addition to EMT transcription factors, miRNAs regulated by ΔNp63α target portions of EMT signaling pathways. The TGFβ pathway can be targeted by multiple miRNA regulated by ΔNp63α, including miR-155, which targets SMAD2 to attenuate TGFβ signaling [62, 63]. ΔNp63α has also been observed to regulate other miRNA that potentially promote EMT, as discussed in the ‘MicroRNAs that promote EMT’ section.

TGFβ signaling is targeted by additional miRNAs, such as the Let-7 miRNA family in human pancreatic cells, and by miR-365 in lung adenocarcinoma [64, 65]. These miRNAs additionally target HMGAA2, indirectly reducing Snail1 expression [66]. A TGFβ receptor, TGFβRII, is inhibited by miR-204. miR-204, miR-1, and miR-203 can directly target SLUG, inhibiting the pathway [67]. Interestingly, SLUG also inhibits the expression of miR-1 and miR-203, in a positive feedback manner [68, 69]. This directly demonstrates a regulatory network between EMT signaling pathways and miRNA.

Supporting a role for miRNA in epithelial integrity, expression levels of E-cadherin are positively correlated with those of miR-205 and the miR-200 miRNA family, which also target ZEB1/2 [70]. The miR-200 family (henceforth referred to as miR-200) consists of five members, including miR-200a, miR-200b, miR-429, miR-200c and miR-141 [71].

### Table 2: miRNAs upregulated by p63

<table>
<thead>
<tr>
<th>miRNA (miR-)</th>
<th>Target Gene(s)</th>
<th>Function</th>
<th>Cell/Tissue Type</th>
<th>Detection method</th>
<th>Reference</th>
</tr>
</thead>
<tbody>
<tr>
<td>17, 106a</td>
<td>MAPK1 (Erk2), p21, RB and MAPK9 (JNK2)</td>
<td>Regulation of keratinocyte differentiation</td>
<td>HaCaT</td>
<td>1,2</td>
<td>[86]</td>
</tr>
<tr>
<td>18a</td>
<td>HIF-1α</td>
<td>Regulation of keratinocyte differentiation</td>
<td>HaCaT</td>
<td>1,2</td>
<td>[86, 126]</td>
</tr>
<tr>
<td>20b</td>
<td>MAPK1, p21 and MAPK9 (JNK2)</td>
<td>Regulation of keratinocyte differentiation</td>
<td>HaCaT</td>
<td>1,2</td>
<td>[86]</td>
</tr>
<tr>
<td>30a</td>
<td>NFATc3, LOX</td>
<td>Regulation of keratinocyte differentiation</td>
<td>HaCaT</td>
<td>1,2</td>
<td>[86, 127, 128]</td>
</tr>
<tr>
<td>92b-3p</td>
<td>HDAC9, KAT2B, ATOX1, CDKN1C</td>
<td>Epigenetic Regulation, Cell Metabolism, Cell Cycle Arrest, Apoptosis</td>
<td>SCC-11</td>
<td>3</td>
<td>[59]</td>
</tr>
<tr>
<td>143</td>
<td>MAPK1 (Erk2)</td>
<td>Regulation of keratinocyte differentiation</td>
<td>HaCaT</td>
<td>1,2</td>
<td>[86]</td>
</tr>
<tr>
<td>155</td>
<td>HIF-1α, FADD, CASP3, SMAD2</td>
<td>Cell Migration, Tumor Growth</td>
<td>MCF10a, A431</td>
<td>2</td>
<td>[63]</td>
</tr>
<tr>
<td>185-5p</td>
<td>ATF6, DNMT1, SREBF2, SREBF4, FADS1, HMGCRCR, CASP2, CASP14, PARP11</td>
<td>Epigenetic Regulation, Cell Metabolism, Cell Cycle Arrest, Apoptosis</td>
<td>SCC-11</td>
<td>3</td>
<td>[87]</td>
</tr>
<tr>
<td>194-3p</td>
<td>GRABARAPL1</td>
<td>Autophagy</td>
<td>SCC-11</td>
<td>3</td>
<td>[87]</td>
</tr>
<tr>
<td>194-5p</td>
<td>KAT6B, SIRT1, ATM, CASP7</td>
<td>Epigenetic Regulation, Cell Cycle Arrest, Apoptosis</td>
<td>SCC-11</td>
<td>3</td>
<td>[88]</td>
</tr>
<tr>
<td>205</td>
<td>ZEB1 and ZEB2</td>
<td>EMT regulation</td>
<td>UC3, UC6</td>
<td>2,4</td>
<td>[60]</td>
</tr>
<tr>
<td>297</td>
<td>DNMT3A, SIRT3, SKP2, ATM, ATP7A, ATG5</td>
<td>Epigenetic Regulation, Cell Metabolism, Autophagy</td>
<td>SCC-11</td>
<td>3</td>
<td>[88]</td>
</tr>
<tr>
<td>382-3p</td>
<td>NFYB, ETNK, CDK1</td>
<td>Epigenetic Regulation, Cell Metabolism, Cell Cycle Arrest, Apoptosis</td>
<td>SCC-11</td>
<td>3</td>
<td>[88]</td>
</tr>
<tr>
<td>455-3p</td>
<td>MAPK8 (JNK1)</td>
<td>Regulation of keratinocyte differentiation</td>
<td>HaCaT</td>
<td>1,2</td>
<td>[86]</td>
</tr>
<tr>
<td>485-5p</td>
<td>KDM4C, ETNK, H6PD, PARP8, DFFA</td>
<td>Epigenetic Regulation, Cell Metabolism, Cell Cycle Arrest, Apoptosis</td>
<td>SCC-11</td>
<td>3</td>
<td>[59]</td>
</tr>
<tr>
<td>610</td>
<td>ATF5</td>
<td>Epigenetic Regulation</td>
<td>SCC-11</td>
<td>3</td>
<td>[85]</td>
</tr>
<tr>
<td>630</td>
<td>EZH2, KAT3B, ZBTB2, UVRAG, ATG2B, ATG4C, ATG12</td>
<td>Epigenetic Regulation Autophagy</td>
<td>SCC-11</td>
<td>3</td>
<td>[87]</td>
</tr>
<tr>
<td>637</td>
<td>ATF3</td>
<td>Epigenetic Regulation</td>
<td>SCC-11</td>
<td>3</td>
<td>[85]</td>
</tr>
<tr>
<td>760</td>
<td>BMF</td>
<td>Cell Cycle Arrest, Apoptosis</td>
<td>SCC-11</td>
<td>3</td>
<td>[85]</td>
</tr>
<tr>
<td>885-3p</td>
<td>CARM1, AKT1, CASP3, ULK2, ATG16</td>
<td>Epigenetic Regulation, Cell Metabolism, Cell Cycle Arrest, Apoptosis, Autophagy</td>
<td>SCC-11</td>
<td>3</td>
<td>[26]</td>
</tr>
<tr>
<td>920</td>
<td>KAT6B, NFYB</td>
<td>Epigenetic Regulation</td>
<td>SCC-11</td>
<td>3</td>
<td>[85]</td>
</tr>
</tbody>
</table>

Detection method: 1: miRNA-microarray, 2: qPCR, 3: miRNA-Chip microarray, 4: ChIP
of ZEB 1/2, miR-200 can also target β-catenin to interrupt EMT signaling [72]. In turn, ZEB1/2 can additionally inhibit transcription of miR-200 family miRNAs, thus there is reciprocal inhibition between ZEB 1/2 and miR-200 [73]. Other miRNAs target individual ZEB isoforms, with ZEB2 targeted by miR-138 and miR-192 [74-76].

Table 3: miRNAs downregulated by p63

<table>
<thead>
<tr>
<th>miRNA (miR-)</th>
<th>Target Gene(s)</th>
<th>Function</th>
<th>Cell/Tissue type</th>
<th>Detection Method</th>
<th>References</th>
</tr>
</thead>
<tbody>
<tr>
<td>7a-5p</td>
<td>CASP3, XIAP</td>
<td>Cell Cycle Arrest, Apoptosis</td>
<td>SCC-11, cervical cancer</td>
<td>3</td>
<td>[85]</td>
</tr>
<tr>
<td>18a-5p</td>
<td>CPS1, CPS2 (CAD), CASP7</td>
<td>Cell Metabolism, Cell Cycle Arrest, Apoptosis</td>
<td>SCC-11</td>
<td>3</td>
<td>[85]</td>
</tr>
<tr>
<td>22-3p</td>
<td>KDM3A, KAT6B, SIRT1, MECP2, ATG2B</td>
<td>Epigenetic Regulation, Autophagy</td>
<td>SCC-11</td>
<td>3</td>
<td>[87]</td>
</tr>
<tr>
<td>25-3p</td>
<td>HDAC9, CDK1C</td>
<td>Epigenetic Regulation, Cell Cycle Arrest, Apoptosis</td>
<td>SCC-11</td>
<td>3</td>
<td>[88]</td>
</tr>
<tr>
<td>27a-3p</td>
<td>HDAC9, KDM3A, p53</td>
<td>Epigenetic Regulation</td>
<td>SCC-11</td>
<td>3</td>
<td>[59]</td>
</tr>
<tr>
<td>29c-3p</td>
<td>DNMT3B, KDM2A, HDAC4, SIRT1, CPS1, AKT2, BMF, CDK2</td>
<td>Epigenetic Regulation, Cell Metabolism, Cell Cycle Arrest, Apoptosis</td>
<td>SCC-11</td>
<td>3</td>
<td>[88]</td>
</tr>
<tr>
<td>34c-3p</td>
<td>BMI1, EED, DNMT1, BMF, ATG4C, DRAM1</td>
<td>Epigenetic Regulation, Cell Cycle Arrest, Apoptosis, Autophagy</td>
<td>SCC-11</td>
<td>3</td>
<td>[88]</td>
</tr>
<tr>
<td>98-5p</td>
<td>CASP3, ATG10</td>
<td>Cell Cycle Arrest, Apoptosis, Autophagy</td>
<td>SCC-11</td>
<td>3</td>
<td>[88]</td>
</tr>
<tr>
<td>101a-3p</td>
<td>EZH2, DNMT3A, COX2, AKT1, ATG4D, RAB5A</td>
<td>Epigenetic Regulation, Cell Metabolism, Autophagy</td>
<td>SCC-11</td>
<td>3</td>
<td>[88]</td>
</tr>
<tr>
<td>130b</td>
<td>ΔNp63α</td>
<td>Senescence</td>
<td>HEKn</td>
<td>1,2</td>
<td>[94]</td>
</tr>
<tr>
<td>138, 181a/b</td>
<td>SIRT-1</td>
<td>Senescence</td>
<td>HEKn</td>
<td>1,2</td>
<td>[94]</td>
</tr>
<tr>
<td>148a-3p</td>
<td>DNMT1, DNMT3B</td>
<td>Epigenetic Regulation</td>
<td>SCC-11, breast and gastric cancers</td>
<td>3</td>
<td>[88]</td>
</tr>
<tr>
<td>155-5p</td>
<td>SP3, KDM2A, KDM5B, APAF1, GABARAPL1</td>
<td>Epigenetic Regulation, Cell Cycle Arrest, Apoptosis, Autophagy</td>
<td>SCC-11</td>
<td>3</td>
<td>[88]</td>
</tr>
<tr>
<td>181a-5p</td>
<td>HDAC4, SIRT1, KAT2B, ATM, ATG, p63</td>
<td>Epigenetic Regulation, Autophagy</td>
<td>SCC-11</td>
<td>3</td>
<td>[87]</td>
</tr>
<tr>
<td>183-5p</td>
<td>RNF5, KDM3A, KDM5B, ATG12</td>
<td>Epigenetic Regulation, Autophagy</td>
<td>SCC-11</td>
<td>3</td>
<td>[85]</td>
</tr>
<tr>
<td>193a-5p, 602, 765</td>
<td>p73</td>
<td>Proliferation, apoptosis</td>
<td>JHU-029 SCC; p63lox mice</td>
<td>1,2,3</td>
<td>[129]</td>
</tr>
<tr>
<td>203a</td>
<td>NFYA, CITED2, KAT6B, ATM, ATP7B, CPS1, PADS1, ATG2B, GABARAPL1, p63</td>
<td>Epigenetic Regulation, Cell Metabolism, Autophagy</td>
<td>SCC-11</td>
<td>3</td>
<td>[88]</td>
</tr>
<tr>
<td>206</td>
<td>CITED, KAT6A</td>
<td>Epigenetic Regulation</td>
<td>SCC-11</td>
<td>3</td>
<td>[88]</td>
</tr>
<tr>
<td>339-3p</td>
<td>DNMT3B, GABARAPL1</td>
<td>Epigenetic Regulation, Autophagy</td>
<td>SCC-11</td>
<td>3</td>
<td>[88]</td>
</tr>
<tr>
<td>362-3p</td>
<td>SIN3A, E2F1</td>
<td>Epigenetic Regulation</td>
<td>SCC-11</td>
<td>3</td>
<td>[85]</td>
</tr>
<tr>
<td>374a-5p</td>
<td>SP1, NPYB, CRTC2, KAT2B, ATM, ATG4A, ATG4A, ATG5, UVRAG, p63</td>
<td>Epigenetic Regulation, Autophagy</td>
<td>SCC-11</td>
<td>3</td>
<td>[46]</td>
</tr>
<tr>
<td>429</td>
<td>CITED2, E2F3, NPYA, CASP2, CDKN2B, CDK2, BCL2</td>
<td>Epigenetic Regulation, Cell Cycle Arrest, Apoptosis</td>
<td>SCC-11</td>
<td>3</td>
<td>[88]</td>
</tr>
<tr>
<td>485-3p</td>
<td>MAPILC3B</td>
<td>Autophagy</td>
<td>SCC-11</td>
<td>3</td>
<td>[85]</td>
</tr>
<tr>
<td>519a-3p</td>
<td>KDM2A, KDM5B, BHLHE31, ATM, CASP2, CDKN2B, ATG10, ATG16L1, UVRAG, p63</td>
<td>Epigenetic Regulation, Cell Cycle Arrest, Apoptosis, Autophagy</td>
<td>SCC-11</td>
<td>3</td>
<td>[46]</td>
</tr>
<tr>
<td>527</td>
<td>TGFβRII, SMAD4</td>
<td>Wound Healing, Migration</td>
<td>JHU-029, MNNG/HOS</td>
<td>1, 2</td>
<td>[95]</td>
</tr>
<tr>
<td>665</td>
<td>TGFβRII, SMAD4</td>
<td>Wound Healing, Migration</td>
<td>JHU-029, MNNG/HOS</td>
<td>1, 2</td>
<td>[95]</td>
</tr>
</tbody>
</table>

Detection method: 1: miRNA-microarray, 2: qPCR, 3: miRNA-Chip microarray
while miR-130b and the miR-34 family, consisting of miR-34a, miR34b, and miR-34c, downregulate ZEB1 expression [74, 77].

The miR-34 family (henceforth referred to as miR-34) also represses EMT through inhibition of SNAIL1 and SLUG expression [78]. Furthermore, while miR-34 can repress SNAIL1, SNAIL1 directly blocks miR-34 transcription, again displaying the reciprocal inhibition that characterizes EMT regulatory pathways [78]. In addition to miR-34, multiple miRNA negatively regulate SNAIL1, such as miR-29b, miR-30, and miR-203, with miR-203 shown to participate in a reciprocal inhibitory loop with Snail1 in breast cancer [79-81]. Interestingly miR-203 also targets ΔNp63α in differentiated keratinocytes demonstrating a potential cell type-specific response [82], with this relationship explored further in the regulation of ΔNp63α by miRNAs section.

Expression of several other miRNAs have also been found to correlate with ΔNp63α expression, and in silico analysis of these miRNAs identified p63 response elements in their promoters. These miRNAs include Let-7, miR-23, miR-29, miR-134, miR-145, miR-192, and miR-215 [83]. In addition to directly targeting miRNA for transcriptional regulation, the p63 gene encodes a Mirtron, miR-944. This miRNA targets transcripts involved in cellular proliferation, migration, and invasion [84]. Moreover, ΔNp63α has also been demonstrated both to upregulate miR-455-3p in an immortalized human keratinocyte cell line and to downregulate it in squamous cell carcinoma, demonstrating potential tissue-specific control of miRNA expression [85, 86]. miR-455-3p targets the RUNX2 transcript to inhibit EMT-promoting components, potentially indicating that ΔNp63α modulation by EMT signaling pathways may also affect miRNA expression profiles [87, 88].

### MICRORNAaS THAT PROMOTE EMT

Certain miRNAs target transcripts of ZEB repressors, stabilizing ZEB expression. For example, miR-221 and miR-222 target the ZEB repressor TRPS1, resulting in E-cadherin downregulation to promote EMT [89]. Additional miRNAs, such as miR-9, can directly target and regulate E-cadherin expression. miR-9 is upregulated by the oncogenes MYC and MYCN, which are often overexpressed in metastatic breast cancer [90]. In a demonstration of tissue-specific activity to induce EMT, miR-9 has also been found to indirectly increase the expression of E-cadherin by targeting NF-κB in melanoma cells, inhibiting Notch signaling and thus acting as a tumor suppressor by indirectly suppressing the expression of SNAIL1 [91]. By contrast, miRNA-10b is known to promote tumor cell invasiveness and is induced by TWIST1. The metastatic action of miR-10b is a result of its inhibition of HOXD10 expression, a transcriptional inhibitor of proteins involved in cell migration and remodeling of the extracellular matrix such as the pro-metastatic protein Rho-Associated, Coiled-Coil Containing Protein Kinase (ROCK) and MMP14 [92, 93].

With miRNAs clearly involved in dual regulation of EMT, miRNAs regulated by ΔNp63α also share this dichotomy. Interestingly, ΔNp63α has been found to

---

### Table 4: miRNAs that downregulate p63

<table>
<thead>
<tr>
<th>miRNA (miR-)</th>
<th>Target Gene(s)</th>
<th>Function</th>
<th>Cell/Tissue type</th>
<th>Detection Method</th>
<th>Reference</th>
</tr>
</thead>
<tbody>
<tr>
<td>130b</td>
<td>ΔNp63α</td>
<td>Senescence</td>
<td>HEKn</td>
<td>1, 2</td>
<td>[94]</td>
</tr>
<tr>
<td>20a-5p</td>
<td>p63</td>
<td>Glycogen synthesis</td>
<td>NCTC1469, Hep1-6</td>
<td>2</td>
<td>[130]</td>
</tr>
<tr>
<td>181a-5p</td>
<td>HDAC4, SIRT1, KAT2B, ATM, ATG5, p63</td>
<td>Epigenetic Regulation, Autophagy</td>
<td>SCC-11</td>
<td>3</td>
<td>[87]</td>
</tr>
<tr>
<td>196a2</td>
<td>TAp63</td>
<td>Proliferation</td>
<td>MCF-7, MDA-MB-231</td>
<td>1,2</td>
<td>[131]</td>
</tr>
<tr>
<td>203</td>
<td>ΔNp63</td>
<td>Epithelial Differentiation, Apoptosis</td>
<td>HEK 293E, NHEK, Primary Mouse Keratinocytes</td>
<td>2</td>
<td>[82]</td>
</tr>
<tr>
<td>203a</td>
<td>NFYA, CITED2, KAT6B, ATM, ATP7B, CPS1, FADS1, ATG2B, GABARAPL1, p63</td>
<td>Epigenetic Regulation, Cell Metabolism, Autophagy</td>
<td>SCC-11</td>
<td>3</td>
<td>[88]</td>
</tr>
<tr>
<td>223-5p</td>
<td>p63</td>
<td>Cell Migration, Invasion</td>
<td>SW962</td>
<td>2</td>
<td>[132]</td>
</tr>
<tr>
<td>92a</td>
<td>p63</td>
<td>Apoptosis, Proliferation</td>
<td>32D, HaCaT, HCT-116-Dicer-KO-2, HL-60</td>
<td>2</td>
<td>[133, 134]</td>
</tr>
<tr>
<td>301a</td>
<td>p63</td>
<td>EMT</td>
<td>PC3, LNCaP</td>
<td>2</td>
<td>[135]</td>
</tr>
<tr>
<td>374a-5p</td>
<td>SP1, NFYB, CRTC2, KAT2B, ATM, ATG4A, ATG5, UVRAG, p63</td>
<td>Epigenetic Regulation, Autophagy</td>
<td>SCC-11</td>
<td>3</td>
<td>[46]</td>
</tr>
</tbody>
</table>

Detection method: 1: miRNA-microarray, 2: qPCR, 3: miRNA-Chip microarray
Figure 2: Role of ΔNp63α in the modulation in EMT with regard to the TGFβ, Wnt, and Notch pathways. A. TGFβ1 and BMP7 signaling results in SMAD phosphorylation and formation of a transcriptional complex with SMAD4 and ΔNp63α to induce EMT. Additionally, ΔNp63α increases TGFβ signaling by upregulating BMP7 transcription. B. ΔNp63α elicits seemingly contradictory effects on Wnt signaling. In normal keratinocytes and adenocarcinoma cell lines, ΔNp63α represses Wnt signaling by competing with β-catenin for Wnt response elements. In invasive carcinoma lines, ΔNp63α promotes β-catenin stability, potentially by inhibiting PTEN and promoting AKTkt phosphorylation and activation, and forms a transcription complex with β-catenin and TCF/LEF to promote EMT. C. PI3K/AKT signaling results in the activation of STAT3 and increased ΔNp63α expression. ΔNp63α then acts through Jagged1 to induce Notch signaling in adjacent cells, leading to increased NF-κB expression and inhibition of ΔNp63α expression to promote EMT.
directly downregulate miRNA involved in the suppression of EMT, such as miR-130b and miR-138. [94]. The TGFβ pathway is promoted by ΔNp63α inhibition of miR-527 and miR-665, resulting in increased TGFβRII and SMAD4 expression [95].

As there are a large number of transcripts involved in EMT regulated by miRNA, regulation of microprocessors such as DICER and DROSHA is integral to the procession of EMT. DICER may be a transcriptional target of p63, as expression of DICER has been found to be influenced by the expression of TAp63. The promoters of several microprocessor components, DROSHA, DGCR8, DICER, and TARBP2, have also been found through computational analysis to have multiple p63 response element sites, with DGCR8 experimentally confirmed to be induced by ΔNp63α [96, 97].

REGULATION OF ΔNP63α BY MICRONRNAS

ΔNp63α itself is a target of multiple miRNAs. miR-203 targets the 3’-UTR of ΔNp63α to decrease cellular proliferation, resulting in repression of epithelial stemness [82]. The miR-203 promoter is hypermethylated in certain cancers and restoration of its expression has been demonstrated to downregulate p63, reduce migration and proliferation in vivo in a Notch dependent manner [98, 99]. miR-92a has similarly been shown to inhibit p63 [100]. Table 4 lists miRNAs validated to downregulate ΔNp63α.

Conversely, other miRNAs have either been demonstrated or have the potential to increase ΔNp63α expression. miR-145 is known to increase the expression of p63 through a mechanism yet to be identified [101]. miRNAs that target inhibitors of ΔNp63α, such as the E3 ubiquitin ligases that target ΔNp63α for proteasomal degradation, have the potential to upregulate ΔNp63α and thereby influence EMT. miR-106b targets ITCH, an E3 ubiquitin ligase that targets ΔNp63α [102, 103]. This is intriguing, as miR-106b has a role in the inhibition of EMT by also targeting TWIST1 [104]. F-box and WD repeat domain-containing 7 (FBW7), another E3 ligase that promotes ΔNp63α degradation, is targeted by miRNAs linked to EMT progression, miR-27a and miR-223 [105-109]. WW domain-containing E3 ubiquitin protein ligase 1 (WWP1), another inhibitor of ΔNp63α expression, is inhibited by miR-21 [110]. miR-21 expression has been correlated with increased p63 expression, and promotes EMT by increasing TGFβ signaling [110, 111]. This relationship is an additional link between miRNAs and EMT promotion through modulation of p63 and EMT signaling. Thus, there is evidence for the potential of miRNA expression patterns to predict the activity of ΔNp63α in the regulation of EMT. It is therefore of value to further investigate the co-regulation of ΔNp63α and miRNAs for the purpose of governing EMT.

CLINICAL RELEVANCE

Due to the role of EMT in the development of key characteristics of metastatic cancer, including increased motility and resistance to apoptosis, there is therapeutic value in researching regulators of EMT. In cancer, there is often a decrease in expression levels of epithelial biomarkers that lead to increased tumor invasiveness and metastasis. For example, a model of pancreatic β-cell carcinogenesis reveals a link with the loss of E-cadherin and a switch from noninvasive adenoma to invasive carcinoma [112]. Additionally, there is an upregulation of Snail and vimentin found in aggressive breast cancers [113, 114]. Furthermore, p63 is often lost in invasive cancers associated with poor patient prognosis [115]. As evidenced by this review, there is a link between miRNAs and ΔNp63α co-regulation with the progression of EMT. Understanding the ΔNp63α-miRNA network would provide crucial information for diagnosis and treatment of EMT-governed tumor metastasis.

miRNAs are increasingly being investigated as biomarkers for premalignant lesions [116]. This is crucial within the context of this review, as patients with elevated expression of EMT biomarkers have a poor prognosis [117]. Along with an increase in metastasis as a result of the loss of E-cadherin observed in patients suffering from colon and prostate cancers, there is also increased expression of SLUG and TWIST1, and decreased expression of E-cadherin associated with increased breast cancer relapse [118-120]. Uncovering the regulation of miRNAs by ΔNp63α involved in EMT progression will therefore help predict tumor progression and patient outcome. For instance, high expression levels of miR-21 and miR-155 (as well as decreased levels of miR-141) in breast cancer and of miR-203 in pancreatic cancer correlate with poor survival [121]. Moreover, miRNA can be assessed through relatively noninvasive means from body fluids such as serum, providing an advantage over traditional biopsies [122].

ΔNp63α and ΔNp63α-regulated miRNAs have utility as predictive biomarkers that can help guide personalized treatment plans to aid in the prevention of metastatic cancer. miRNA expression profiles and miRNA biomarkers that correlate with cancerous and normal phenotypes are now routinely identified using Next Generation Sequencing. miRNA that regulate ΔNp63α in EMT may therefore serve as novel therapeutic targets for inhibiting metastasis, either via blockade of metastasis-inducing miRNAs through antagonistic mRNA-mimic complementary base pairing or through exogenous introduction of miRNAs that induce tumor-suppressing effects [123]. Finally, miRNA expression profiles may also have the potential to predict the outcome of a therapeutic regimen [124].
CONCLUSIONS

There is growing evidence for the involvement of EMT in the development of metastatic cancers, with implications in breast, lung, prostate, bladder, and gastric cancers. Identifying the mechanisms by which EMT induces a motile and invasive cell phenotype is therefore valuable in combating the various types of malignant carcinoma.

This review presents information from multiple studies detailing the diverse involvement of miRNAs and ΔNp63α in the development of EMT-mediated metastatic cancer. miRNAs have emerged as regulators of key EMT transcripts, whose expression patterns could indicate the genomic balance indicative of EMT. The transcription factor ΔNp63α has been shown to regulate multiple miRNAs in addition to cell signaling pathways, including TGFβ, Wnt, and Notch, involved in EMT, as described throughout this review. Since ΔNp63α expression and activity are altered by these signaling pathways to either promote or antagonize EMT, ΔNp63α-regulated miRNAs will also be altered in a similar manner. Understanding ΔNp63α-regulated miRNA profiles could therefore provide clues as to whether specific cancer types will become migratory and invasive. This highlights the importance of uncovering the regulatory network of miRNAs by ΔNp63α within the context of EMT.

Principally, identification of ΔNp63α-regulated miRNAs as novel biomarkers may provide a powerful tool for the prediction of metastatic potential. Further, Next Generation Sequencing may facilitate generation of a miRNA profile of cells undergoing EMT. With further study, such profiling has the potential to create a more personalized patient prognosis and therapeutic development for treatment of high-risk invasive tumors.

ACKNOWLEDGMENTS

We would like to thank Dr. Natasha Hill for her editorial and scientific guidance.

CONFLICTS OF INTEREST

The authors declare no conflict of interest.

GRANT SUPPORT

This work was supported by grant1R01CA154715 (MK) from the National Institutes of Health.

REFERENCES

17. Serber Z, Lai HC, Yang A, Ou HD, Sigal MS, Kelly AE,
Oncotarget

www.impactjournals.com/oncotarget


 research. 2015; 75(18):3925-3935.


70. Park SM, Gaur AB, Lengyel E and Peter ME. The miR-200 family determines the epithelial phenotype of cancer cells by targeting the E-cadherin repressors ZEB1 and ZEB2. Genes & development. 2008; 22(7):894-907.


84. Stinson S, Lackner MR, Adai AT, Yu N, Kim HJ,


111. Odar K, Bostjancic E, Gale N, Glavac D and Zidar N.


